{
    "body": "Has Revlimid been approved by the US Food and Drug Administration?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25188481", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17996589", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25188483", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23545923", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17076650", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17076653", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20425391", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17242661", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18922829", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22650376", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17020458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20359632"
    ], 
    "ideal_answer": [
        "Yes, Revlimid has been approved by the US Food and Drug Administration for treatment of multiple myeloma."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014486"
    ], 
    "type": "yesno", 
    "id": "56ed0ba22ac5ed1459000007", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 461, 
            "text": "In the past decade, immunomodulatory drugs have been approved by the US Food and Drug Administration for the treatment of multiple myeloma (MM)-and a number of emerging agents that target the cellular pathways or proteins involved in the pathophysiology of MM are currently in development. Lenalidomide (Revlimid) and pomalidomide induce apoptosis and sensitize MM cells while demonstrating superior efficacy and better tolerability than thalidomide (Thalomid).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188483", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 290, 
            "text": "In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188481", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 289, 
            "text": "In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188481", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 697, 
            "offsetInEndSection": 941, 
            "text": "Thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade) are directed not only at MM cells but also at the BM milieu and have moved rapidly from the bench to the bedside and United States Food and Drug Administration approval to treat MM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17996589", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 303, 
            "text": "Lenalidomide (CC-5013, Revlimid; Celgene Corporation, Summit, NJ), a thalidomide analogue, was granted approval by the U.S. Food and Drug Administration (FDA) on June 29, 2006, for use in combination with dexamethasone in patients with multiple myeloma (MM) who have received at least one prior therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18922829", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 280, 
            "text": "Lenalidomide, an IMiD drug (a novel type of immunomodulating drug) was recently approved by the US Food and Drug Administration for the treatment of transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS) and interstitial deletions of chromosome 5q [del(5q)]", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17242661", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 309, 
            "offsetInEndSection": 537, 
            "text": "Lenalidomide, a second-generation immunomodulatory drug (IMiD), is approved by the US Food and Drug Administration for treatment of transfusion-dependent anemia in lower-risk MDS patients with deletion 5q chromosomal abnormality", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425391", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 290, 
            "text": "In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188481", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 35, 
            "offsetInEndSection": 129, 
            "text": "lenalidomide (CC5103 or revlimid) are recently approved for the treatment of multiple myeloma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22650376", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 462, 
            "text": " In the past decade, immunomodulatory drugs have been approved by the US Food and Drug Administration for the treatment of multiple myeloma (MM)-and a number of emerging agents that target the cellular pathways or proteins involved in the pathophysiology of MM are currently in development. Lenalidomide (Revlimid) and pomalidomide induce apoptosis and sensitize MM cells while demonstrating superior efficacy and better tolerability than thalidomide (Thalomid).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188483", 
            "endSection": "abstract"
        }
    ]
}